WO2008104956A2 - Procédé de préparation de cabergoline amorphe - Google Patents

Procédé de préparation de cabergoline amorphe Download PDF

Info

Publication number
WO2008104956A2
WO2008104956A2 PCT/IB2008/050735 IB2008050735W WO2008104956A2 WO 2008104956 A2 WO2008104956 A2 WO 2008104956A2 IB 2008050735 W IB2008050735 W IB 2008050735W WO 2008104956 A2 WO2008104956 A2 WO 2008104956A2
Authority
WO
WIPO (PCT)
Prior art keywords
cabergoline
amorphous
organic solvent
process according
thin film
Prior art date
Application number
PCT/IB2008/050735
Other languages
English (en)
Other versions
WO2008104956A3 (fr
Inventor
Anshul Agrawal
Sushil K. Yadav
Sanjay Gade
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2008104956A2 publication Critical patent/WO2008104956A2/fr
Publication of WO2008104956A3 publication Critical patent/WO2008104956A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides

Definitions

  • the present invention relates to processes for the preparation of amorphous cabergoline by agitated thin film drying or spray drying.
  • Cabergoline is indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.
  • GB 2,074,566 B provides a process for preparing cabergoline, wherein the final product is isolated as a diphosphate salt.
  • WO 03/078433 provides a process for preparing a mixture of amorphous cabergoline and Form I, by drying the toluene solvate Form V.
  • WO 04/094368 provides processes for preparing amorphous cabergoline from tert-butyl methyl ether solvate Form A by vacuum drying or lyophilization.
  • WO 05/085243 provides a process for preparing amorphous cabergoline, wherein the process involves dissolving chromatographically purified oily cabergoline in acetone and partially removing the solvent several times in vacuum.
  • the present inventors have developed novel processes for preparing amorphous cabergoline.
  • the present processes do not require lyophilization or repeated crystallizations.
  • the present process is simple and provides amorphous cabergoline in a single step by agitated thin film drying or spray drying.
  • the present processes also provide amorphous cabergoline substantially free from crystalline contamination.
  • collecting includes unloading, amassing, gathering, scaling and/or piling.
  • a process for the preparation of amorphous cabergoline comprises, a) dissolving cabergoline in an organic solvent, b) removing the solvent from the solution obtained in step a) by agitated thin film drying, and c) collecting amorphous cabergoline from the agitated thin film dryer.
  • Cabergoline present in any solid or solvated form known to the person skilled in the art can be used as a starting material.
  • Cabergoline present in oily form can also be used as a starting material.
  • the starting material of cabergoline can be prepared according to the methods provided in the prior art references, for example, WO 03/078433.
  • the cabergoline is dissolved in an organic solvent.
  • the organic solvent is selected from a group consisting of acetone, diethyl ether, cyclohexane and isopropanol.
  • the organic solvent is preferably acetone.
  • the solution so obtained is filtered and fed to an agitated thin film dryer.
  • the solvent is subsequently removed from the solution by agitated thin film drying.
  • the drying process is accompanied by heating at a temperature of about 35 0 C or above.
  • the feeding rate of the solution is controlled in such a way to facilitate the thin film formation and the evaporation rate.
  • the rotor and vapor duct can have a sealing system so that the drying can preferably be carried under vacuum. Vacuum operation also facilitates amorphous cabergoline to be obtained without degradation.
  • the amorphous cabergoline is collected from the agitated thin film dryer.
  • the amorphous cabergoline can optionally be further dried under vacuum to obtain amorphous cabergoline with desired residual solvent content.
  • the amorphous cabergoline so obtained has substantially the same XRPD pattern as depicted in Figure 1.
  • a process for the preparation of amorphous cabergoline comprises, a) dissolving cabergoline in an organic solvent, b) removing the solvent from the solution obtained in step a) by spray drying, and c) collecting amorphous cabergoline from the spray dryer.
  • Cabergoline for use as the starting material in the processes described herein can be prepared according to the methods provided in the prior art references, for example, WO
  • Cabergoline is dissolved in an organic solvent.
  • the organic solvent is selected from a group consisting of acetone, diethyl ether, cyclohexane and isopropanol.
  • the organic solvent is preferably acetone.
  • the solution is filtered and fed to a spray dryer.
  • the inlet and outlet temperatures, feed rate, and atomizer type can be adjusted to optimize output and particle size.
  • the air inlet temperature is preferably controlled from about 5O 0 C to about 80 0 C.
  • the outlet temperature is preferably controlled from about 35 0 C to about 45 0 C.
  • an inert gas for example, nitrogen gas can be used as a carrier gas.
  • the cabergoline is collected from the spray dryer and optionally further dried under vacuum to obtain amorphous cabergoline with desired residual solvent content.
  • the amorphous cabergoline so obtained has substantially the same XRPD pattern as depicted in Figure 2.
  • Figure 1 depicts XRPD of amorphous cabergoHne obtained by agitated thin film drying.
  • Figure 2 depicts XRPD of amorphous cabergoline obtained by spray drying.
  • Powder XRD of the samples were determined by using X-Ray Difractometer, Rigaku Corporation, RU-H3R, Goniometer CN2155A3, X-Ray tube with Cu target anode, Divergence slits 1 0, Receiving slit 0.15mm, Scatter slit 1°, Power: 40 KV, 100 mA, Scanning speed: 2 deg/min step: 0.02 deg, Wave length: 1.5406 A.
  • Nozzle Diameter 0.5 mm
  • Carrier gas Nitrogen at 2 to 2.2 kg/cm 2 Air inlet temperature: 50°-52°C Outlet temperature: 45°C
  • Type of atomizer Two fluids nozzle

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des procédés de préparation de cabergoline amorphe par séchage de film mince par agitation ou par séchage par pulvérisation.
PCT/IB2008/050735 2007-02-28 2008-02-28 Procédé de préparation de cabergoline amorphe WO2008104956A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN450DE2007 2007-02-28
IN450/DEL/2007 2007-02-28

Publications (2)

Publication Number Publication Date
WO2008104956A2 true WO2008104956A2 (fr) 2008-09-04
WO2008104956A3 WO2008104956A3 (fr) 2009-08-13

Family

ID=39672747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/050735 WO2008104956A2 (fr) 2007-02-28 2008-02-28 Procédé de préparation de cabergoline amorphe

Country Status (1)

Country Link
WO (1) WO2008104956A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094368A2 (fr) * 2003-04-21 2004-11-04 Finetech Laboratories, Ltd. Formes nouvelles de cabergoline
WO2005085243A2 (fr) * 2004-03-04 2005-09-15 Richter Gedeon Vegyészeti Gyár Rt. Nouveau procede de production de la cabergoline

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094368A2 (fr) * 2003-04-21 2004-11-04 Finetech Laboratories, Ltd. Formes nouvelles de cabergoline
WO2005085243A2 (fr) * 2004-03-04 2005-09-15 Richter Gedeon Vegyészeti Gyár Rt. Nouveau procede de production de la cabergoline

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ASHFORD S W ET AL: "A practical synthesis of cabergoline" JOURNAL OF ORGANIC CHEMISTRY, vol. 67, no. 20, 4 October 2002 (2002-10-04), pages 7147-7150, XP002491857 USA ISSN: 0022-3263 cited in the application *

Also Published As

Publication number Publication date
WO2008104956A3 (fr) 2009-08-13

Similar Documents

Publication Publication Date Title
JP5247728B2 (ja) ベンズイミダゾール誘導体の製造方法
EP2951158B1 (fr) Procédé de préparation d'ivacaftor et de solvates de celui-ci
CZ299215B6 (cs) Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
WO2008104512A3 (fr) Composés organiques
CZ2007455A3 (cs) Zpusob izolace a cištení montelukastu
WO2013024492A2 (fr) Procédé de préparation d'asénapine et nouveaux sels de celle-ci
EP2114868A2 (fr) Nouvelles formes polymorphes d'hydrochlorure de milnacipran
EP2432788A1 (fr) Fosamprenavir calcique amorphe
WO2008104956A2 (fr) Procédé de préparation de cabergoline amorphe
EP2077903A2 (fr) Procédé de préparation de la forme i et de la forme ii du ritonavir
WO2013088373A1 (fr) Chlorhydrate de vilazodone amorphe, procédé pour sa préparation et compositions pharmaceutiques correspondantes
EP1831171A1 (fr) Processus de preparation de nouveau montelukast sodique amorphe
WO2011061613A1 (fr) Procédé de préparation de la forme cristalline ii du sel d'acide malique l du sunitinib
EP1860105A1 (fr) Procédé de préparation de desloratadine
EP2373651A1 (fr) Nouvelles formes polymorphes d'un dérivé d'azabicyclo-trifluorométhyl benzamide
US20110224435A1 (en) Process for preparation of amorphous lopinavir
CN106432253B (zh) 一种维帕他韦新晶型及其制备方法
WO2009150524A1 (fr) Procédé de préparation d’un dérivé de benzoylbenzène acétamide
WO2004089281A2 (fr) Nouveaux corps polymorphes de tartrate de tolterodine
CN110746340A (zh) 一种5-甲氧基-2-甲基色胺的合成方法
WO2011058521A2 (fr) Procédé de préparation de la forme cristalline i du sel d'acide l-malique de sunitinib
WO2012131389A1 (fr) Procédé pour la préparation de 1-(2-méthyl-4-(2,3,4,5-tétrahydro-1- benzazépin-1-ylcarbonyl)benzylcarbamoyl)-l-proline-n,n-diméthylamide
US20120267533A1 (en) Processes for the preparation of form i and form ii of palonosetron hydrochloride
EP3207040A1 (fr) Procédé de préparation d'azilsartan très pur
CN113087619A (zh) 一种酮咯酸氨丁三醇中间体化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08719514

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08719514

Country of ref document: EP

Kind code of ref document: A2